PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers
Primary Purpose
Peripheral Neuropathy Pain
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
YHD1119
Lyrica
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Neuropathy Pain
Eligibility Criteria
Inclusion Criteria:
- Healthy male with body mass index (BMI) between 18.5 and 28 kg/m2
- Who has not suffered from clinically significant disease
- Provision of signed written informed consent
Exclusion Criteria:
- History of and clinically significant disease
- A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs
- Administration of other investigational products within 3 months prior to the first dosing
Sites / Locations
- Chonbuk National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
YHD1119 (Pregabalin 300mg)
Lyrica (Pregabalin 150mg)
Arm Description
YHD1119 (Pregabalin 300mg)
Lyrica (Pregabalin 150mg)
Outcomes
Primary Outcome Measures
Cohort 1: Cmax
Cohort 1: AUCtau
Cohort 1: Cmax
Cohort 1: AUCtau
Cohort 2: Cmax
Cohort 2: AUCtau
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02783638
Brief Title
PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers
Official Title
A Open-label, Randomized, Crossover Clinical Trial to Assess the PK of Pregabalin CR After Multiple Dosing as Compared to Pregabalin IR and the Food Effect of High Fat Diet After Single Dosing in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
January 2016 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
September 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yuhan Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is to assess the pharmacokinetics of Pregabalin controlled release formulation after multiple dosing as compared to Pregabalin immediate release formulation and the food effect of high fat diet after single dosing in healthy male volunteers.
Detailed Description
Cohort 1 study is to assess the PK of Pregabalin controlled release formulation as compared to Pregabalin immediate release formulation. Cohort 1 subjects will be admitted to the clinic at Day 1. All subjects will receive multiple dosing for three days of YHD1119 or Pregabalin IR and will remain in the clinic until completion of all assessment on Day 19 including collection of PK sample. The treatment periods were separated by a washout period (10-17 days).
Cohort 2 study is to assess the food effect of high fat diet after single dosing. Cohort 2 subjects will be admitted to the clinic at Day -1. All subjects will receive a single dose of YHD1119 and will remain in the clinic until completion of all assessment on Day 9 including collection of PK sample. The treatment periods were separated by a washout period (7-14 days).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Neuropathy Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
64 (Actual)
8. Arms, Groups, and Interventions
Arm Title
YHD1119 (Pregabalin 300mg)
Arm Type
Experimental
Arm Description
YHD1119 (Pregabalin 300mg)
Arm Title
Lyrica (Pregabalin 150mg)
Arm Type
Active Comparator
Arm Description
Lyrica (Pregabalin 150mg)
Intervention Type
Drug
Intervention Name(s)
YHD1119
Other Intervention Name(s)
Pregabalin 300mg
Intervention Description
2 by 2
Intervention Type
Drug
Intervention Name(s)
Lyrica
Other Intervention Name(s)
Pregabalin 150mg
Intervention Description
2 by 2
Primary Outcome Measure Information:
Title
Cohort 1: Cmax
Time Frame
Lyrica(Pregabalin 150mg): 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
Title
Cohort 1: AUCtau
Time Frame
Lyrica(Pregabalin 150mg): 0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours
Title
Cohort 1: Cmax
Time Frame
YHD1119(Pregabalin 300mg): 1,2,3,4,5,6,8,10,12,16,24,36 hours
Title
Cohort 1: AUCtau
Time Frame
YHD1119(Pregabalin 300mg): 1,2,3,4,5,6,8,10,12,16,24,36 hours
Title
Cohort 2: Cmax
Time Frame
YHD1119(Pregabalin 300mg): 1,2,3,4,5,6,8,10,12,16,24,36 hours
Title
Cohort 2: AUCtau
Time Frame
YHD1119(Pregabalin 300mg): 1,2,3,4,5,6,8,10,12,16,24,36 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male with body mass index (BMI) between 18.5 and 28 kg/m2
Who has not suffered from clinically significant disease
Provision of signed written informed consent
Exclusion Criteria:
History of and clinically significant disease
A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs
Administration of other investigational products within 3 months prior to the first dosing
Facility Information:
Facility Name
Chonbuk National University Hospital
City
Jeonju
ZIP/Postal Code
561-712
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers
We'll reach out to this number within 24 hrs